Tagetes patula flower extract; Tagetes patula flower oil: EU cosmetic annex conditions and formula evidence
Tagetes patula flower extract; Tagetes patula flower oil has identifier matches to Annex III in the acquired 18 May 2026 EU Cosmetics Regulation text. The table distinguishes the substance identity, product-use conditions and recorded limits. Confirm the exact substance/group scope, formula concentration and intended use before applying an entry. This does not certify formula safety or settle Great Britain requirements.
Evidence retrieved 2026-10-06. Source versions and topic-specific limits are listed below.
Exact legal-entry matches and product-use conditions
Exact checksum-valid CAS and/or exact EC identifier in preserved legal identity cells. Group and substance scope are still conditional.
Each line below retains its own concentration basis, conditions and warnings. Blank source cells mean no condition was recorded in that cell; they do not establish unrestricted use.
Annex III · Entry 308
Recorded identity: Tagetes minuta flower extract ( 24 ) Tagetes minuta flower oil ( 25 )
Matching CAS: 8016-84-0 · Matching EC: No exact EC match
Product use / body site
Maximum concentration and basis
Other conditions
Warnings
Source
(a) Leave-on products
(a) 0,01 %
For (a) and (b): Alpha terthienyl (terthiophen) content in the extract/oil ≤ 0,35 %. For (a): Not to be used in sunscreen products and products marketed for exposure to natural/artificial UV light. For (a) and (b): In case of combined use with Tagetes patula (entry 309), the total combined content of Tagetes in ready for use preparation shall not exceed the maximum concentration limits set out in column (g).
For (a) and (b): Alpha terthienyl (terthiophen) content in the extract/oil ≤ 0,35 %. For (a): Not to be used in sunscreen products and products marketed for exposure to natural/artificial UV light. For (a) and (b): In case of combined use with Tagetes patula (entry 309), the total combined content of Tagetes in ready for use preparation shall not exceed the maximum concentration limits set out in column (g).
►C5 ( 24 ) From 1 May 2019 cosmetic products containing that substance and not complying with the restrictions shall not be placed on the Union market. From 1 August 2019 cosmetic products containing that substance and not complying with the restrictions shall not be made available on the Union market. [3]
( 25 ) From 1 May 2019 cosmetic products containing that substance and not complying with the restrictions shall not be placed on the Union market. From 1 August 2019 cosmetic products containing that substance and not complying with the restrictions shall not be made available on the Union market. [4]
For (a) and (b): Alpha terthienyl (terthiophen) content in the extract/oil ≤ 0,35 %. For (a): Not to be used in sunscreen products and products marketed for exposure to natural/artificial UV light. For (a) and (b): In case of combined use with Tagetes minuta (entry 308), the total combined content of Tagetes in ready for use preparation shall not exceed the maximum concentration limits set out in column (g).
For (a) and (b): Alpha terthienyl (terthiophen) content in the extract/oil ≤ 0,35 %. For (a): Not to be used in sunscreen products and products marketed for exposure to natural/artificial UV light. For (a) and (b): In case of combined use with Tagetes minuta (entry 308), the total combined content of Tagetes in ready for use preparation shall not exceed the maximum concentration limits set out in column (g).
( 26 ) From 1 May 2019 cosmetic products containing that substance and not complying with the restrictions shall not be placed on the Union market. From 1 August 2019 cosmetic products containing that substance and not complying with the restrictions shall not be made available on the Union market. [7]
( 27 ) From 1 May 2019 cosmetic products containing that substance and not complying with the restrictions shall not be placed on the Union market. From 1 August 2019 cosmetic products containing that substance and not complying with the restrictions shall not be made available on the Union market. ◄ [8]
The consolidated text is a dated reference. Current amendments, corrigenda and applicability dates must be checked. EU evidence does not resolve Great Britain rules.
Known facts and deciding inputs
Known context: EU. Ingredient identity is recorded; concentration, intended use, exposure and current legal conditions still need checking.
Check identity, concentration, exposure and use against the current legal annex and any amendments.
other
For (a) and (b): Alpha terthienyl (terthiophen) content in the extract/oil ≤ 0,35 %.
For (a): Not to be used in sunscreen products and products marketed for exposure to natural/artificial UV light.
For (a) and (b): In case of combined use with Tagetes minuta (entry 308), the total combined content of Tagetes in ready for use preparation shall not exceed the maximum concentration limits set out in column (g). [1]
Check identity, concentration, exposure and use against the current legal annex and any amendments.
Check identity, concentration, exposure and use against the current legal annex and any amendments.
Resolve the entry against your actual formula
Use this checklist to gather your business or product details before speaking with a specialist. The items below explain what to record and suggest useful supporting documents. You can add your own answers in the editable project brief.
Does the supplied material fall within these exact entries?
Put your supplier CAS/EC, substance composition, salt/group membership, purity, physical form and intended function beside each matched entry. A matching identifier does not resolve every group or impurity condition.
Useful evidence: Supplier specification, composition and certificates of analysis; the exact annex rows above.
Which row governs the finished-product use?
Compare the finished-product concentration, body site, rinse-off/leave-on use, consumer/professional setting and any exposure restrictions with each row. Preserve the units and calculation basis; do not transfer a limit from a different product-use row.
Useful evidence: Quantitative formula and use instructions; a row-by-row condition and warning worksheet.
Is a prohibition or trace question involved?
For Annex II matches, review Article 14 before formulation decisions. Article 17 concerns a separate, conditional non-intended trace situation; it does not grant blanket permission to intentionally add a prohibited substance. Record origin and technical-avoidability evidence for specialist review.
Useful evidence: Ingredient/impurity origin, manufacturing controls, trace quantities and the cited Article 17 text.
What must reach the safety assessor and Responsible Person?
Send the reconciled identity, condition table, exposure facts, supplier evidence and unresolved amendment/date questions. Agree formula, assessment and PIF responsibilities before notification or manufacturing handoff.
Useful evidence: A dated formula-evidence matrix, supplier data, exposure description and document ownership list.
Work packages and dependencies
Conditional: Formula-condition reconciliation and EU safety/PIF handoff — Resolve the matched annex entries against supplier identity, function, concentration basis, product use, warnings and linked notes. Agree assessment, PIF and Responsible Person responsibilities after the findings.
Optional: Manufacturing and supplier-evidence handoff — If manufacturing support is needed, prepare material specifications, quantitative formula, batch controls and the condition/warning evidence matrix for the assessor and Responsible Person.
What needs to happen first
EU+UK Cosmetics Compliance → Cosmetic Contract Manufacturers & Private Label: Resolve the formula-condition and warning questions before agreeing manufacturing release evidence; coordinate the assessor, Responsible Person and manufacturer handoff.
Questions for providers
Which exact annex entry and product-use subrow matches our material and finished-product use, and which alternatives should be excluded?
What evidence resolves group/salt, impurity, concentration-basis and warning conditions in the matched rows?
Which amendments or applicability dates change this dated reference, and how will EU and GB evidence be checked separately?
Sources and data dates
Read the official document in context. The audit details identify the precise locators and preserved versions used for this page.
[2] HTML table[2] in substantive document container (extraction legal-html-tables-2) / own tr[586] · record 46d1a6d78e0438ad1744a485673b02c22bf5455fb19a831f2668edd9d98d7589
[3] #E0043 / containing div (linked annex note) · record 1f29d80632a3d3dfb78e0888e07da965f5bba7c4747ddfdf4e16ed039a5725b1
[4] #E0044 / containing div (linked annex note) · record 6a10f866af215f960664c120cf66c3c91b80403862294552419d15be652d05b9
[5] HTML table[2] in substantive document container (extraction legal-html-tables-2) / own tr[587] · record 563da4b0c14928ab21f56c09357b82b62980376e9cb5a012aa9ae80279c160ee
[6] HTML table[2] in substantive document container (extraction legal-html-tables-2) / own tr[588] · record 9359d9a9d9e3b4224c6960510cc4063b62ea07ce42e3d901cab4c1f5a4356270
[7] #E0045 / containing div (linked annex note) · record 62fcdcebd0c49005406c398188c5164c71bd70a03c55fba3b2000c1a2a919f65
[8] #E0046 / containing div (linked annex note) · record bccb8453d10c650b91ecd4a1e4b4b435b8dc444eecaf77197c07128ce1da9c99
[9] HTML table[2] in substantive document container (extraction legal-html-tables-2) / own tr[589] · record f495faa9901cf728dbea3c4a265b94ffe4f847cc44a4004dd84e989ef0f1ff4a
[10] #art_14 · record 9ffeb5c563a32fe8d532de5d352c05f8a9062e1c5d21fd326d5e6c2ea42a84f4
[11] #art_17 · record 8ad3194ae1fc45e70495aa637f90457139a0023680e2b880fc4c8a8b4d202c43
[12] #art_10 · record 49eb173406b736d6f0b855572abc53b0f52d9543a4d170affa8ae68d6e809718
[13] #art_11 · record ba70c2a84c1d6c70eb57a0fd892fcdf584f6142281b03c29be4bd20e6e83844d
Prepare an editable project brief
Confirm the facts, scope and contact preference before sharing your project. Preparing this page sends no provider outreach.
